41 completed, 2 withdrawn, 1 recruiting, 1 terminated. 46 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Completed 41, Withdrawn 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Alprazolam: new trials by email Literature Review of Alprazolam trials Research Report on Alprazolam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Opioid Drug Interaction Study Alprazolam, Oxycodone, Placebo - Drug Interactions, Drug Kinetics | Phase 1 / Phase 2 | Recruiting | Shanna Babalonis, PhD | 25 | 2025-04-01 | 2026-05-14 |
| A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants Staccato alprazolam, Oral alprazolam - Healthy Participants | Phase 1 | Completed | UCB Biopharma SRL | 21 | 2022-12-28 | 2024-03-18 |
| A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg - Healthy Volunteers | Phase 1 | Completed | Takeda | 100 | 2022-11-15 | 2026-09-16 |
| Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD) - Driving Behavior, Driving Under the Influence | Phase 1 | Completed | Timothy L. Brown | 13 | 2021-07-16 | 2023-07-25 |
| A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy Alprazolam - Epilepsy | Phase 1 | Completed | UCB Biopharma SRL | 14 | 2021-04-28 | 2022-06-30 |
| A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma Alprazolam, Placebo - Healthy Study Participants, Participants With Mild Asthma | Phase 1 | Completed | UCB Biopharma SRL | 78 | 2021-03-09 | 2023-11-28 |
| Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants Alprazolam, Placebo - Healthy Study Participants | Phase 1 | Completed | UCB Biopharma SRL | 30 | 2021-03-04 | 2021-05-17 |
| Role of Alprazolam in the Management of Acute Coronary Syndrome Alprazolam, Placebo - Acute Coronary Syndrome, Myocardial Infarction | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 48 | 2020-12-25 | 2021-01-20 |
| A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects CVL-865 High dose, Alprazolam 1mg XR, Placebo - Panic Disorder | Phase 1 | Completed | Cerevel Therapeutics, LLC | 56 | 2020-10-06 | 2022-01-11 |
| Licorice Botanical Dietary Supplements - Metabolism and Safety in Women Licorice, Alprazolam 2 MG, Caffeine 100 MG - Food-drug Interaction | Phase 1 | Completed | University of Illinois at Chicago | 19 | 2019-04-01 | 2023-05-06 |
| Assessment of Effect of Rapastinel on Driving Performance Rapastinel, Alprazolam, Ketamine - Driving Performance | Phase 1 | Completed | Naurex, Inc, an affiliate of Allergan plc | 107 | 2018-11-05 | 2019-07-11 |
| Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Gamma-Aminobutyric Acid (GABA), Alprazolam - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Per-Ola Carlsson | 35 | 2018-09-05 | 2022-11-02 |
| Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam THC, Alprazolam, Placebo oral capsule - Cannabis Use Disorder | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 42 | 2017-12-04 | 2018-06-14 |
| A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users Lasmiditan, Alprazolam, Placebo - Recreational Drug Use, Prescription Drug Abuse (Not Dependent) | Phase 1 | Completed | Eli Lilly and Company | 96 | 2017-09-15 | 2020-01-10 |
| Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free) Benzodiazepine - limited use strategy, Benzodiazepine - Ad libitum strategy - Post-operative Delirium | Phase 1 | Completed | McMaster University | 480 | 2017-04-01 | 2018-10-16 |
| A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users Alprazolam Placebo, Cenobamate placebo, Alprazolam - Healthy Volunteer | Phase 1 | Completed | SK Life Science, Inc. | 53 | 2017-03-08 | 2024-11-07 |
| The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants Lasmiditan, Alprazolam, Placebo - Migraine | Phase 1 | Completed | Eli Lilly and Company | 90 | 2017-01-16 | 2020-01-10 |
| MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers Jelly with:Paracetamol, Jelly with Furosemide, Jelly with Levothyroxine sodium salt - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Nice | 16 | 2014-06-01 | 2015-10-07 |
| An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites Xanax XR tablets 3 mg (sourced from Caugus), Xanax XR tablets 3 mg (sourced from Barceloneta) - Healthy Subjects | Phase 1 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 16 | 2011-05-01 | 2021-01-28 |
| Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation alprazolam commercial immediate release oral tablet, alprazolam test sublingual tablet - Healthy | Phase 1 | Withdrawn | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2011-04-01 | 2021-01-28 |
Showing 20 of 46. Sign in to see all of them.
Anxiety Disorders (10) · Substance-Related Disorders (2) · Acute Coronary Syndrome (1) · Alzheimer Disease (1) · Depression (1) · Depressive Disorder (1) · Diabetes Mellitus, Type 1 (1) · Driving Under the Influence (1) · Emergence Delirium (1) · Epilepsy (1) · Heart Diseases (1) · Huntington Disease (1) · Hypercapnia (1) · Marijuana Abuse (1) · Migraine Disorders (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (6) · GlaxoSmithKline (5) · Actavis Inc. (4) · UCB Biopharma SRL (4) · Mylan Pharmaceuticals Inc (3) · Pfizer (3) · Eli Lilly and Company (2) · Orion Corporation, Orion Pharma (2) · Sandoz (2) · Teva Pharmaceuticals USA (2) · Centre Hospitalier Universitaire de Nice (1) · Cerevel Therapeutics, LLC (1) · McMaster University (1) · National Institute on Drug Abuse (NIDA) (1) · Naurex, Inc, an affiliate of Allergan plc (1)
United States (25) · Canada (4) · Finland (2) · France (1) · India (1) · Mexico (1) · Netherlands (1) · Pakistan (1) · Singapore (1) · Spain (1) · Sweden (1) · United Kingdom (1)
James D. Carlson,, Pharm.D, (4) · Dorian Williams, M.D. (3) · James D. Carlson, Pharm. D. (2) · Aila Holopainen, M. Sc. (1) · Aila Holopainen, M.Sc. (1) · Calvin F. Fuhrmann, M.D. (1) · Debra Kelsh, MD (1) · Gabriel Etienne Jacobs, PhD, MD (1) · Niloufar Guiv, M.D. (1) · Per-Ola Carlsson, MD, PhD (1) · Qazi Abdul Saboor, MBBS (1)
PMID 25199955, PMID 29671186, PMID 32416996, PMID 34423904, PMID 34635547, PMID 41747804
R01DA016718 (1)